XERIANT INC (XERI) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 23, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-K for FY2026, filed Sep 28, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the XERI SEC filings page.
This page shows XERIANT INC (XERI) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
The reported business remains balance-sheet-driven: positive FY2026 earnings coexist with negative equity and liabilities far above assets.
FY2026 liabilities were$2.11M , or2122.7% of assets, even after liabilities fell67.3% from FY2024—showing balance-sheet contraction without solvency repair. Meanwhile, FY2026 net income of$392K coexisted with-$2.01M equity, so improved reported earnings did not repair the capital structure.
The statements do not support normal operating analysis because revenue and operating cash flow are unreported; FY2026 SG&A of
Negative equity persisted from FY2022 through FY2026 while liabilities exceeded assets in every reported year. In FY2024, financing cash flow of
Financial Health Signals
XERIANT INC does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The metrics below are current.
Key Financial Metrics
Earnings & Revenue
XERIANT INC earned $0.00 per diluted share (EPS) in Q4 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
Not reported for Q4 2026.
Not reported for Q4 2026.
Not reported for Q4 2026.
Cash & Balance Sheet
XERIANT INC recorded an outflow of $184K in free cash flow in Q4 2026, representing a cash shortfall after capex. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative.
XERIANT INC held $88K in cash as of Q4 2026; no long-term debt figure is on record for that period.
Not reported for Q4 2026.
Margins & Returns
None of these metrics is reported for Q4 2026.
Capital Allocation
XERIANT INC reported no capital expenditure in Q4 2026. This represents a decrease of 100.0% from the same quarter a year earlier.
Not reported for Q4 2026.
Not reported for Q4 2026.
XERI Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q4'2610-K | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q |
|---|---|---|---|---|---|---|---|---|
| R&D Expenses | N/A | $30K-1.9% | $16K+108586.7% | $54K+103.2% | N/A | $30K-55.2% | $15-100.0% | $27K-1.6% |
| SG&A Expenses | N/A | $59K-42.5% | $28K-80.5% | $25K-55.9% | N/A | $102K+49.4% | $146K+99.9% | $56K+7.7% |
| Operating Income | N/A | N/A | -$231Kn/m | -$304Kn/m | N/A | N/A | -$336Kn/m | -$359Kn/m |
| EBITDA | N/A | N/A | -$231Kn/m | -$304Kn/m | N/A | N/A | -$335Kn/m | -$358Kn/m |
| Interest Expense | N/A | $46K-31.1% | $36K-30.3% | $45K-27.3% | N/A | $66K+131.6% | $51K | $62K+198.0% |
| Income Tax | N/A | -$24Kn/m | -$16Kn/m | $125Kn/m | N/A | $0n/m | $0n/m | $0n/m |
| Net Income | N/A | N/A | -$298Kn/m | N/A | N/A | N/A | -$417K | -$372Kn/m |
| EPS (Basic) | $0.00n/m | $0.00n/m | $0.00n/m | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| EPS (Diluted) | $0.00n/m | $0.00n/m | $0.00n/m | $0.00 | $0.00n/m | $0.00n/m | $0.00n/m | $0.00 |
| Diluted Shares (Avg) | N/A | 882M+34.7% | 780M+30.8% | 2.37B | N/A | 655M+45.7% | 596M+40.8% | 548M |
Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit.
XERI Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q4'2610-K | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $99K+45.8% | $44K-40.2% | $103K-62.6% | $72K-79.8% | $68K-90.4% | $73K-83.8% | $277K+114.4% | $355K+38.3% |
| Current Assets | $91K+60.9% | $34K-45.4% | $95K-64.7% | $62K-80.7% | $57K-91.5% | $62K-84.1% | $269K+402.8% | $320K+90.2% |
| Cash & Equivalents | $88K+95.3% | $25K-54.2% | $77K-69.9% | $52K-82.6% | $45K-93.1% | $54K-85.7% | $254K+552.1% | $300K+1122.0% |
| Short-Term Investments | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m |
| Long-Term Investments | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m |
| Total Liabilities | $2.1M-64.2% | $3.0M-48.8% | $2.9M-53.0% | $2.9M-51.6% | $5.9M-8.9% | $5.8M-32.8% | $6.1M-23.6% | $6.0M-16.3% |
| Non-Current Liabilities | N/A | -$2.9Mn/m | -$2.9M | -$2.9M | -$2.9Mn/m | -$2.9Mn/m | N/A | N/A |
| Long-Term Debt | N/A | $0 | $508 | $2K | $3K | N/A | N/A | N/A |
| Total Equity | -$2.0Mn/m | -$2.9Mn/m | -$2.8Mn/m | -$2.8Mn/m | -$5.8Mn/m | -$5.7Mn/m | -$5.8Mn/m | -$5.6Mn/m |
| Retained Earnings | -$27.9Mn/m | -$26.8Mn/m | -$26.4Mn/m | -$26.1Mn/m | -$28.3Mn/m | -$28.0Mn/m | -$27.5Mn/m | -$27.1Mn/m |
Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill, Current Liabilities.
XERI Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q4'2610-K | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$184Kn/m | N/A | -$206Kn/m | -$178Kn/m | -$172Kn/m | -$366Kn/m | -$398Kn/m | -$353Kn/m |
| Depreciation & Amortization | $615+32.3% | $465+23.0% | $465+23.0% | $465+23.0% | $465+23.0% | $3780.0% | $3780.0% | $3780.0% |
| Stock-Based Compensation | N/A | $162K+224.0% | $35K+141.3% | $60K-72.6% | N/A | $50Kn/m | $15Kn/m | $218Kn/m |
| Capital Expenditures | $0-100.0% | N/A | N/A | N/A | $2Kn/m | N/A | N/A | N/A |
| Free Cash Flow | -$184Kn/m | N/A | N/A | N/A | -$174Kn/m | N/A | N/A | N/A |
| Investing Cash Flow | $0n/m | -$3Kn/m | $0n/m | $0n/m | -$2Kn/m | $0n/m | $0n/m | $0-100.0% |
| Financing Cash Flow | $248K+50.0% | $175K+6.1% | $230K-34.7% | $185Kn/m | $165K-74.6% | $165K-78.0% | $352K | $0n/m |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
XERI Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Return on Equity, Current Ratio, Debt-to-Equity, Liabilities-to-Equity, Asset Turnover, FCF Margin.
Note: Shareholder equity is negative (-$2.0M), which causes the debt-to-equity, liabilities-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| XERIANT INC XERI | FY2026 | N/A | $392K | N/A | $10.3M | — |
| HELIO CORPORATION HLEO | FY2025 | $3.9M | -$4.0M | N/A | $24.9M | — |
Where XERIANT INC Ranks
Frequently Asked Questions
Is XERIANT INC profitable?
Yes, XERIANT INC (XERI) reported a net income of $392K in fiscal year 2026.
What are XERIANT INC's total assets?
XERIANT INC (XERI) had $99K in total assets as of fiscal year 2026, including both current and long-term assets.
What are XERIANT INC's capital expenditures?
XERIANT INC (XERI) invested $3K in capital expenditures during fiscal year 2026, funding long-term assets and infrastructure.
How much does XERIANT INC spend on research and development?
XERIANT INC (XERI) invested $100K in research and development during fiscal year 2026.
What is XERIANT INC's return on assets (ROA)?
XERIANT INC (XERI) had a return on assets of 394.4% for fiscal year 2026, measuring how efficiently the company uses its assets to generate profit.
What is XERIANT INC's P/E ratio?
XERIANT INC (XERI) trades at 26.3x earnings, its market capitalization divided by $392K net income, FY2026. The market capitalization is $10.3M as of Oct 23, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is XERIANT INC's price-to-sales ratio?
XERIANT INC (XERI) has no price-to-sales ratio at the moment: no revenue reported. The market capitalization is $10.3M as of Oct 23, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
Why is XERIANT INC's debt-to-equity ratio negative or not reported?
XERIANT INC (XERI) has negative shareholder equity of -$2.0M as of fiscal year 2026, so no debt-to-equity or liabilities-to-equity ratio is reported: dividing debt by equity that is not positive produces a number that cannot be read as leverage. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.